Follow
Anna He
Title
Cited by
Cited by
Year
Predicting free choices for abstract intentions
CS Soon, AH He, S Bode, JD Haynes
Proceedings of the National Academy of Sciences 110 (15), 6217-6222, 2013
2782013
Tracking the unconscious generation of free decisions using uitra-high field fMRI
S Bode, AH He, CS Soon, R Trampel, R Turner, JD Haynes
PloS one 6 (6), e21612, 2011
2122011
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ...
The Lancet Neurology 19 (4), 307-316, 2020
1352020
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ...
JAMA neurology 72 (4), 405-413, 2015
1132015
Hyperdense middle cerebral artery sign is associated with increased risk of hemorrhagic transformation after intravenous thrombolysis for patients with acute ischaemic stroke
M Zou, L Churilov, A He, B Campbell, SM Davis, B Yan
Journal of Clinical Neuroscience 20 (7), 984-987, 2013
382013
Early start of high-efficacy therapies improves disability outcomes over 10 years
A He, B Merkel, L Zhovits, I Kister, C Malpas, S Sharmin, D Horakova, ...
MULTIPLE SCLEROSIS JOURNAL 24, 497-498, 2018
32018
Rituximab infusion timing, cumulative dose, and hospitalization for COVID-19 in persons with multiple sclerosis in Sweden
KA McKay, F Piehl, S Englund, A He, A Langer-Gould, J Hillert, T Frisell
JAMA network open 4 (12), e2136697-e2136697, 2021
22021
8.: Comparison of switch to fingolimod or interferon beta/glatiramer acetate as second line therapy in active multiple sclerosis
A He, T Spelman, V Jokubaitis, H Butzkueven, T Kalincik, ...
Journal of Clinical Neuroscience 21 (11), 2035-2036, 2014
12014
Differences in quality of care between neurology clinics-do they correlate to patient outcomes? A nationwide observational study.(P8-4.004)
A He, A Manouchehrinia, J Hillert, K McKay
Neurology 98 (18 Supplement), 2022
2022
Earlier disease modifying therapy is associated with more favourable long-term patient reported outcomes in relapsing multiple sclerosis
A He, J Hillert, T Spelman, O Ciccarelli, K McKay
MULTIPLE SCLEROSIS JOURNAL 27 (2_ SUPPL), 281-281, 2021
2021
No association between rituximab infusion timing nor cumulative dose and hospitalization for COVID-19: Evidence from the nationwide COMBAT-MS Cohort
KA McKay, F Piehl, S Englund, A He, A Langer-Gould, J Hillert, T Frisell
Multiple Sclerosis Journal, 60-61, 2021
2021
Lower Long-Term Disability with Early Start of High-Efficacy Therapies in Multiple Sclerosis (1182)
A He, B Merkel, JW Brown, LZ Ryerson, I Kister, C Malpas, D Horakova, ...
Neurology 94 (15 Supplement), 2020
2020
Erratum: Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis (JAMA Neurology (2015) 72: 4 (405-413))
A He, T Spelman, V Jokubaitis
JAMA Neurology 72 (8), 2015
2015
Comparison of fingolimod versus interferon beta/glatiramer acetate as second-line therapy in active multiple sclerosis
A He, T Spelman, V Jokubaitis, A Lugaresi, G Izquierdo, M Trojano, ...
MULTIPLE SCLEROSIS JOURNAL 20, 193-193, 2014
2014
The system can't perform the operation now. Try again later.
Articles 1–14